Treatment of chronic hepatitis C virus infection - Dutch national guidelines

Netherlands Journal of Medicine

Volumn 66, Issue 7, 2008, Pages 311-322

  de Bruijne, J ^a   Buster, E H C J ^b   Gelderblom, H C ^a   Brouwer, J T ^c   de Knegt, R J ^b   van Erpecum, K J ^d   Schalm, S W ^b   Bakker, C M ^e   Zaaijer, H L ^a   Janssen, H L A ^b   Reesink, H W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; VIRUS RNA;

AGITATION; ALOPECIA; ANEMIA; ANOREXIA; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BIOCHEMISTRY; BLOOD EXAMINATION; BLOOD TRANSFUSION; CARDIOTOXICITY; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONCENTRATION LOSS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG RESPONSE; ECHOGRAPHY; ECZEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; GOUT; HEARING LOSS; HEMOLYSIS; HEPATITIS C; HUMAN; INJECTION SITE ERYTHEMA; INSOMNIA; INTERSTITIAL PNEUMONIA; IRRITABILITY; LEUKOPENIA; LIBIDO DISORDER; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MENTAL INSTABILITY; MONOTHERAPY; MOTIVATION; MYALGIA; NAUSEA; NETHERLANDS; NEUTROPENIA; NOSE OBSTRUCTION; OPTIC NEURITIS; OUTPATIENT CARE; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT MONITORING; POLYNEUROPATHY; PRURITUS; RELAPSE; RETINOPATHY; SEIZURE; SIDE EFFECT; SJOEGREN SYNDROME; SUICIDAL IDEATION; TASTE; THROMBOCYTOPENIA; TREATMENT DURATION; VIRAL GENETICS; VIRUS LOAD;

ANTIVIRAL AGENTS; GUIDELINES AS TOPIC; HEPATITIS C, CHRONIC; HUMANS; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 48749124393     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Anonymous. Hepatitis C - global prevalence (update). Weekly Epidemiological Record 1999;74:425-427.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
3. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095-2100.
4. Hattum van HJ. Health strategy on HCV in The Netherlands. Acta Gastroenterol Belg 2002;65:115-117.
5. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006;12:1192-1204.
6. Brown RS. Hepatitis C and liver transplantation. Nature 2005;436:973-978.
7. Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007;13:975-983.
8. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36:S3-20.
9. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-264.
10. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
11. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004;39:1213-1219.
12. Wawrzynowicz-Syczewska M, Kubicka J, Lewandowski Z, Boron-Kaczmarska A, Radkowski M. Natural history of acute symptomatic hepatitis type C. Infection 2004;32:138-143.
13. Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med 1996;335:631-634.
14. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003;43:721-729.
15. Kolk DP, Dockter J, Linnen J, et al. Significant closure of the human immunodeficiency virus type 1 and hepatitis C virus preseroconversion detection windows with a transcription-mediated-amplification-driven assay. J Clin Microbiol 2002;40:1761-1766.
16. Busch MP, Rawal BD, Feibig EW, Operskalski EA, Mosley JW. Dynamics of HCV viremia and seroconversion in transfusion-acquired HCV infections. Transfusion 1998;38(Suppl):265.
17. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-979.
18. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.
19. Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:450-453.
20. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002;42:980-988.
21. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003;84:274-286.
22. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-1359.
23. Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002;99:4588-4591.
24. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999;31 Suppl 1:9-16.
25. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-1310.
26. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46.
27. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
28. Tanaka Y, Hanada K, Mizokami M, et al. Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A 2002;99:15584-15589.
29. Kenny-walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
30. Posthouwer D, Makris M, Yee TT, et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007;109:3667-3671.
31. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study. J Hepatol 2005;43:590-598.
32. Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 1993;119:110-115.
33. Agnello V, De Rosa FG. Extrahepatic disease manifestations of HCV infection: some current issues. J Hepatol 2004;40:341-352.
34. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 2005;17:447-455.
35. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lances 2006;368:938-945.
36. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005;43:550-552.
37. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-538.
38. www.emea.europa.eu/humandocs/PDFs/EPAR/Pegintron/H-280-Pl-nl.pdf. PegIntron (peginterferon-alfa-2b) summary of product characteristics.
39. www.emea.europa.eu/humandocs/PDFs/EPAR/Rebetol/H-246-Pl-nl.pdf. Rebetol (ribavirine) summary of product characteristics.
40. www.roche.nl/producten/spc/peg180S.pdf. Pegasys (peginterferon-alfa-2a) summary of product characteristics.
41. www.roche.nl/producten/spc/cop200tab.pdf. Copegus (ribavirine) summary of product characteristics.
42. Bianca S, Ettore G. Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects. Birth Defects Res A Clin Mol Teratol 2003;67:77-78.
43. Hillyard IW. The preclinical toxicology and safety of ribavirin. In: Smith RA, Kirkpatrick W (Eds). Ribavirin: a broad spectrum antiviral agent. New York: Academic Press 1980;59-72.
44. Johnson EM. Developmental toxicity and safety evaluations of ribavirin. Pediatr Infect Dis J (1990;9:S85-S87.
45. Polifka JE, Friedman JM. Developmental toxicity of ribavirin/IFalpha combination therapy: is the label more dangerous than the drugs? Birth Defects Res A Clin Mol Teratol 2003;67:8-12.
46. Rezvani M, Koren G. Pregnancy outcome after exposure to injectable ribavirin during embryogenesis. Reprod Toxicol 2006;21:113-115.
47. FDA Pregnancy Category X http://a257.g.akamaitech.net/7/257/2422/ 14mar20010800/edocket.access.gpo.gov/cfr_2003/aprqtr/pdf/21cfr201.57.pdf
48. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
49. Trevisani F, De NS, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-744.
50. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422.
51. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004;19:715-727.
52. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55:1-33.
53. Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96-100.
54. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV infected African American and white patients treated with IFN and ribavirin. Hepatology 2003;37:1343-1350.
55. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-2271.
56. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-1186.
57. Berg T, Sarrazin C, Herrmann E, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003;37:600-609.
58. Weegink CJ, Sentjens RE, Beld MG, Dijkgraaf MG, Reesink HW. Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. J Viral Hepat 2003;10:174-182.
59. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
60. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
61. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
62. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
63. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504-1508.
64. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-960.
65. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-999.
66. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.
67. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
68. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-S244.
69. Jansen PL, Reesink HW. Antiviral effect of peginterferon alfa-2b and alfa-2a compared. J Hepatol 2006;45:172-173.
70. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-981.
71. Jacobson IM, Brown RS Jr, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007;46:982-990.
72. Ferenci P, Bergholz U, Laferl H, et al. Is shorter treatment with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (COPEGUS (R)) possible in HCV genotype 1 'super-responders'? preliminary results of a prospective randomized clinical trial. Hepatology 2005;42:218A.
73. Ferenci P, Scherzer T, Laferl H, et al. High SVR rate, with 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS (R)) plus ribavirin (COPEGUS (R)) in HCV genotype 1 or 4 patients with a week-4 virological response. J Clin Virol 2006;36:S50.
74. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-1265.
75. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42.
76. Lagging M, Langeland N, Pedersen C, et al. Comparison of Peginterferon alfa-2a and Ribavirin for 12 or 24 weeks in patients with HCV genotype 2/ 3:the NORDynamIC trial. ABSTRACT EASL 2007.46 ed. 2007.
77. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617.
78. Shiffman M, Minola E, Barange K, et al. Characterisation of hepatitis C virus genotype 2/3 patients without a rapid virological response (RVR): optimising treatment by predicting slower responders to peginterferon alfa-2a (40 KD) (PEGASYS(r)) plus ribavirin (COPEGUS(r)) ABSTRACT EASL 2007. 46 ed. 2007.
79. Shiffman M, Pappas S, Bacon B, et al. Utility of virological response at weeks 4 and 12 in the prediction of SVR rates in genotype 2/3 patients treated with Peginterferon alfa-2a (40kd) plus ribavirin: Findings from accelerate. Hepatology 2006;44:316A-317A.
80. Shiffman M, Pappas S, Greenbloom S, et al. Effect of drug exposure on sustained virological response (SVR) in patients with chronic hepatitis C virus genotype 2 or 3 treated with Peginterferon alfa-2a (40kd) (PEGASYS (R)) plus ribavirin (COPEGUS (R)) for 16 or 24 weeks. Hepatology 2006;44:317A-318A.
81. Shiffman ML, Pappas S, Nyberg L, et al. Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the accelerate trial. J Hepatol 2006;44:S271.
82. Wagner von M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527.
83. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559.
84. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-2451.
85. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003;13:547-551.
86. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-433.
87. Lukasiewicz E, Hellstrand K, Westin J, et al Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV RNA at day 0, day 22, day 29, and week 6. Hepatology 2007;45:258-259.
88. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
89. Bezemer G, Schalm SW, van Gool AR, de Knegt RJ. [Changes in the management of patients with side effects from the treatment of hepatitis C]. Ned Tijdschr Geneeskd 2007;151:525-530.
90. Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-1678.
91. Renou C, Harafa A, Cummins C, et al. Threshold for neutropenia in the adjustment of interferon treatment in HCV infection. Hepatology 2003;37:949-950.
92. Soza A, Everhart JE, Chany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-1279.
93. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-1929.
94. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med 2004;164:2371-2376.
95. Doi F, Kakizaki S, Takagi H, et al. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 2005;25:242-246.
96. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol 2006;21:319-326.
97. Moncoucy X, Leymarie F, Delemer B, et al. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005;29:339-345.
98. McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44:411-421.
99. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006;43:S207-S220.
100. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002.
101. www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html. HCV Advocate.
102. www.hcvdrugs.com. Hepatitis C New Drug Pipeline.
103. www.hivandhepatitis.com/hep_c.html. HIV and Hepatitis.com.